Figure 3 : Receiver operating characteristic AUC values for 30 highest rated by AUC pathway markers.

From: In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development

Figure 3

Pathway markers of responders/non-responders to paclitaxel for ERN HER2P (left) and ERN HER2N (right) breast cancer treatment were obtained using iPANDA. Up and downregulated pathways in responders group compared with non-responders group are shown in red and blue, respectively. The saturation of the colour denotes to corresponding AUC value. The same signalling pathways are found to be markers of responders/non-responders to paclitaxel treatment for four (ERN HER2P) or five (ERN HER2N) independent data sets obtained from GEO. Nineteen and eight pathway markers for ERN HER2P and ERN HER2N breast cancer, respectively, demonstrate AUC values higher than 0.7 for all data sets examined.